Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Panacea Biotec Ltd.
Swot
Panacea Biotec Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Panacea Biotec Ltd. has 17 Strengths, 6 Weaknesses, 0 Opportunities and 0 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(17)
Weakness
(6)
Opportunity
(0)
Threats
(0)
Others
(6)
Benjamin Graham Value Screen
Consistent Highest Return Stocks over Five Years
Turnaround Companies: Loss to Profit QoQ
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Turnaround companies- loss to profit QoQ
Growth in Net Profit with increasing Profit Margin (QoQ)
Companies with Low Debt
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
Negative to Positive growth in Sales and Profit with Strong Price momentum
RSI indicating price strength
MACD crossed above zero line previous end of day
Top Gainers
PE higher than Industry PE
High PE (PE > 40)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Low Piotroski Score : Companies with weak financials
Declining profitability: Falling ROCE
Stocks Underperforming their Industry Price Change in the Quarter
Stocks with improving cash flow, with good durability
Rising Delivery Percentage Compared to Prev Day
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
High PE with Negative ROE
Decline in Quarterly Net Profit with falling Profit Margin (YoY)